AMPH

Amphastar Pharmaceuticals, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · amphastar.com

$22.74

Mkt Cap $1.0B

52w Low $17.03 40.1% of range 52w High $31.26

50d MA $21.07 200d MA $25.08

P/E (TTM) 10.4x

EV/EBITDA 11.7x

P/B 1.3x

Debt/Equity 0.8x

ROE 22.0%

P/FCF 10.3x

RSI (14) —

ATR (14) —

Beta 0.91

50d MA $21.07

200d MA $25.08

Avg Volume 518.2K

About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary r…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 26, 2026	AMC	0.90	0.73	-19.2%	26.49	-15.3%	-23.6%	-20.7%	-25.1%	-24.7%	-22.8%	-27.4%	—
Nov 6, 2025	AMC	0.77	0.93	+20.8%	24.23	+7.9%	-0.8%	+7.8%	+12.1%	+14.9%	+8.8%	+7.3%	—
Aug 7, 2025	AMC	0.71	0.85	+19.7%	21.62	+3.1%	+10.1%	+26.5%	+40.4%	+41.0%	+39.7%	+35.3%	—
May 7, 2025	AMC	0.66	0.74	+12.1%	24.43	+0.7%	+0.9%	-1.3%	-0.4%	-2.3%	-4.6%	+6.4%	—
Feb 27, 2025	AMC	1.01	0.92	-8.9%	31.49	-3.1%	-9.7%	-12.6%	-12.3%	-10.9%	-10.1%	-7.9%	—
Nov 6, 2024	AMC	0.99	0.96	-3.0%	53.40	-10.2%	-13.7%	-9.5%	-9.0%	-10.7%	-14.8%	-18.0%	—
Aug 7, 2024	AMC	0.77	0.94	+22.1%	38.89	+9.3%	+13.3%	+10.2%	+11.2%	+12.0%	+9.1%	+16.7%	—
May 8, 2024	AMC	0.96	1.04	+8.3%	42.21	+7.9%	+0.5%	+0.0%	+0.4%	-2.2%	+0.5%	-3.6%	—
Feb 28, 2024	AMC	0.93	0.88	-5.4%	54.74	-9.0%	-14.9%	-15.6%	-14.7%	-13.5%	-15.4%	-20.6%	—
Nov 8, 2023	AMC	0.69	1.15	+66.7%	45.42	+5.7%	+15.4%	+15.7%	+17.9%	+24.0%	+26.6%	+25.0%	—
Aug 8, 2023	AMC	0.56	0.65	+16.1%	65.00	-0.5%	-4.3%	-17.8%	-15.9%	-16.8%	-11.9%	-21.2%	—
May 9, 2023	AMC	0.48	0.62	+29.2%	36.44	+3.4%	+13.0%	+14.4%	+14.2%	+14.6%	+17.8%	+25.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 21	Jefferies	Downgrade	Buy → Hold	$22	$22.92	$22.38	-2.4%	-7.5%	-8.4%	-8.3%	-6.6%	-5.5%
Apr 8	Barclays	Maintains	Equal Weight → Equal Weight	—	$20.58	$20.68	+0.5%	-0.9%	+1.4%	-1.0%	+3.8%	+3.9%
Feb 27	Needham	Maintains	Buy → Buy	—	$26.49	$22.44	-15.3%	-23.6%	-20.7%	-25.1%	-24.7%	-22.8%
Feb 27	Wells Fargo	Maintains	Overweight → Overweight	—	$26.49	$22.44	-15.3%	-23.6%	-20.7%	-25.1%	-24.7%	-22.8%
Nov 7	Needham	Maintains	Buy → Buy	—	$24.23	$26.15	+7.9%	-0.8%	+7.8%	+12.1%	+14.9%	+8.8%
Oct 22	Needham	Maintains	Buy → Buy	—	$24.26	$24.14	-0.5%	+1.1%	+1.9%	+1.1%	-0.9%	-0.3%
Aug 26	BofA Securities	Maintains	Neutral → Neutral	—	$29.83	$29.98	+0.5%	+1.7%	+2.2%	+1.4%	+2.6%	+3.3%
Aug 12	Needham	Upgrade	Hold → Buy	—	$27.36	$28.18	+3.0%	+10.9%	+11.4%	+10.4%	+9.0%	+8.8%
Aug 8	Piper Sandler	Maintains	Neutral → Neutral	—	$21.62	$22.29	+3.1%	+10.1%	+26.5%	+40.4%	+41.0%	+39.7%
May 12	JP Morgan	Downgrade	Overweight → Neutral	—	$24.11	$24.05	-0.2%	+1.0%	-1.0%	-3.4%	+0.9%	+3.1%
May 8	Wells Fargo	Maintains	Overweight → Overweight	—	$24.43	$24.59	+0.7%	+0.9%	-1.3%	-0.4%	-2.3%	-4.6%
Apr 10	Needham	Maintains	Hold → Hold	—	$25.23	$24.99	-1.0%	-6.8%	-4.2%	-3.2%	-6.9%	-8.9%
Mar 21	Piper Sandler	Maintains	Neutral → Neutral	—	$27.91	$27.66	-0.9%	+1.4%	+2.0%	+1.7%	+1.6%	+2.1%
Feb 4	Piper Sandler	Downgrade	Overweight → Neutral	—	$33.39	$32.42	-2.9%	-0.6%	-1.8%	-1.8%	-3.1%	-3.5%
Aug 8	Piper Sandler	Maintains	Overweight → Overweight	—	$38.89	$42.49	+9.3%	+13.3%	+10.2%	+11.2%	+12.0%	+9.1%
Jun 27	Piper Sandler	Maintains	Overweight → Overweight	—	$40.03	$40.20	+0.4%	+0.8%	-0.1%	-3.8%	-6.1%	-3.7%
May 17	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$42.94	$43.10	+0.4%	+0.1%	+2.1%	+2.8%	+3.1%	+1.8%
Oct 25	Piper Sandler	Maintains	Overweight → Overweight	—	$30.88	$30.84	-0.1%	-4.0%	-0.9%	-1.7%	+0.3%	+0.1%
Jul 29	Capital One	Maintains	Overweight → Overweight	—	$37.27	$37.62	+0.9%	+0.3%	-0.8%	+0.3%	+0.1%	-0.8%
Mar 15	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$34.81	$34.49	-0.9%	-0.2%	-1.7%	-1.8%	-1.7%	+1.8%
Mar 11	Piper Sandler	Maintains	Overweight → Overweight	—	$30.47	$30.00	-1.5%	+12.6%	+14.2%	+14.0%	+12.3%	+12.2%
Jan 7	Piper Sandler	Upgrade	Neutral → Overweight	—	$23.18	$23.75	+2.5%	+8.1%	+11.4%	+9.1%	+10.5%	+7.5%
Mar 17	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$18.44	$18.27	-0.9%	-2.4%	-2.9%	-2.0%	+0.3%	-2.4%
Jan 8	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$20.65	$19.02	-7.9%	-4.1%	-5.4%	-5.5%	-6.1%	-6.7%
Oct 5	Northland Capital Markets	Upgrade	Market Perform → Outperform	—	$19.00	$20.30	+6.8%	+6.0%	+6.4%	+7.6%	+10.1%	+11.8%
Jul 9	Northland Capital Markets	Downgrade	Outperform → Market Perform	—	$21.50	$21.09	-1.9%	-3.2%	-5.4%	-8.1%	-5.7%	-3.8%
May 11	BMO Capital	Maintains	Market Perform → Market Perform	—	$18.79	$18.80	+0.1%	+2.1%	-1.4%	-1.5%	-4.3%	-3.2%
Mar 13	Needham	Downgrade	Buy → Hold	—	$24.17	$21.50	-11.0%	-14.4%	-15.2%	-16.3%	-15.7%	-14.7%
Mar 13	BMO Capital	Maintains	Market Perform → Market Perform	—	$19.58	$19.72	+0.7%	+3.9%	+3.4%	+1.1%	+1.7%	-0.1%
Nov 10	BMO Capital	Maintains	Market Perform → Market Perform	—	$18.81	$18.73	-0.4%	-1.4%	-5.1%	-5.6%	-5.1%	-3.5%
Nov 9	Raymond James	Downgrade	Outperform → Market Perform	—	$17.81	$17.00	-4.5%	+5.6%	+4.2%	+0.3%	-0.3%	+0.3%
Mar 14	Raymond James	Downgrade	Strong Buy → Outperform	—	$14.74	$13.96	-5.3%	-17.2%	-8.9%	-9.4%	-6.7%	-3.2%
Aug 9	Jefferies	Maintains	Buy → Buy	—	$16.02	$17.80	+11.1%	+12.0%	+13.4%	+16.5%	+13.0%	+14.7%
Jun 29	BMO Capital	Maintains	Market Perform → Perform	—	$16.63	$16.59	-0.2%	-3.3%	-3.1%	-2.1%	-1.8%	+0.4%
Feb 19	Wells Fargo	Maintains	Outperform → Outperform	—	$11.18	$11.18	+0.0%	+1.6%	+2.5%	-0.6%	+0.2%	-0.4%
Jan 19	Jefferies	Maintains	Buy → Buy	—	$12.29	$12.35	+0.5%	-2.2%	+1.9%	-0.2%	-0.3%	-1.4%
Nov 13	Jefferies	Maintains	Buy → Buy	—	$12.26	$12.14	-1.0%	+13.4%	+12.6%	+15.7%	+20.3%	+17.4%
Jun 3	Raymond James	Downgrade	Strong Buy → Buy	—	$15.79	$16.04	+1.6%	+4.4%	+4.3%	+4.2%	+4.9%	+2.8%
Mar 25	Jefferies	Maintains	Buy → Buy	—	$15.33	$15.50	+1.1%	-5.9%	-2.5%	+0.7%	-2.4%	-2.4%
Aug 13	Jefferies	Maintains	Buy → Buy	—	$10.20	$9.80	-3.9%	-0.5%	-0.7%	-0.5%	-1.8%	-1.9%
Jul 21	PiperJaffray	Maintains	Overweight → Overweight	—	$9.55	$9.70	+1.6%	-2.1%	-0.5%	-4.3%	-3.5%	-6.0%
Jul 21	Jefferies	Maintains	Buy → Buy	—	$9.55	$9.70	+1.6%	-2.1%	-0.5%	-4.3%	-3.5%	-6.0%
Jul 21	Needham	Maintains	Buy → Buy	—	$9.55	$9.70	+1.6%	-2.1%	-0.5%	-4.3%	-3.5%	-6.0%
Jul 21	BMO Capital	Maintains	Outperform → Outperform	—	$9.55	$9.70	+1.6%	-2.1%	-0.5%	-4.3%	-3.5%	-6.0%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

AMPH filed a generic 8-K with minimal substantive disclosure, suggesting either a routine procedural matter or incomplete filing that provides no clear fundamental catalyst for the stock.

Mar 16

8-K

Amphastar Pharmaceuticals, Inc. -- 8-K Filing

Amphastar Pharmaceuticals appointed a new executive with competitive compensation including $590,000 base salary, performance bonuses up to 53% of base, and equity incentives, signaling management continuity and potential strategic leadership changes.

Mar 6

8-K · 1.01 !! High

Amphastar Pharmaceuticals, Inc. -- 8-K 1.01: Supply Agreement

Amphastar Pharmaceuticals entered a supply agreement with Nanjing Letop Biotechnology, expanding its pharmaceutical sourcing capabilities and potentially strengthening its product pipeline.

Mar 6

8-K

Amphastar Pharmaceuticals, Inc. -- 8-K Filing

Amphastar Pharmaceuticals reported fourth quarter and full-year 2025 financial results, demonstrating operational performance across its generic and proprietary injectable, inhalation, and intranasal product portfolio.

Feb 26

Data updated apr 24, 2026 5:52pm · Source: massive.com